23 peptides in this category. Click any to open its calculator.
GLP-1 and related incretin compounds act on appetite and glucose signalling rather than on fat tissue directly. This group contains the approved medicines in the catalogue — semaglutide, tirzepatide, liraglutide — alongside investigational triple agonists still in Phase 3. Approved products follow a fixed weekly escalation set out in the label; the research compounds have no approved human dose at all. Each calculator converts a vial strength and a water volume into a syringe reading, and shows the titration schedule that the trials or the label actually used. One practical warning applies across the whole group: a cycling schedule with scheduled breaks does not appear in any approved label here, and the labels that exist specify continuous weekly use. Where a table shows cycles, it is community convention, not a trial design.
